Piperazine designer drugs of abuse

Lancet

Volumn 369, Issue 9571, 2007, Pages 1411-1413

  Staack, Roland F ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 1 (3,4 METHYLENEDIOXYBENZYL)PIPERAZINE; 1 (4 METHOXYPHENYL)PIPERAZINE; 1 BENZYLPIPERAZINE DERIVATIVE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; COCAINE; DESIGNER DRUG; PHENCYCLIDINE DERIVATIVE; PHENETHYLAMINE DERIVATIVE; PIPERAZINE; UNCLASSIFIED DRUG;

ARTICLE; AUSTRALIA; DEATH; DRUG INTOXICATION; EUROPE; INTERNET; JAPAN; LAW; PRIORITY JOURNAL; UNITED KINGDOM; UNITED STATES;

EID: 34247547059     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60646-1     Document Type: Note

References (13)

1. Wood D., Dargan P., Button J., et al. Pills, collapse, and a negative drug screen. Lancet 369 (2007) 1490
2. Balmelli C., Kupferschmidt H., Rentsch K., and Schneemann M. Fatal brain edema after ingestion of ecstasy and benzylpiperazine. Dtsch Med Wochenschr 126 (2001) 809-811
3. Gee P., Richardson S., Woltersdorf W., and Moore G. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. N Z Med J 118 (2005) U1784
4. Wikström M., Holmgren P., and Ahlner J. A2 (N-benzylpiperazine) a new drug of abuse in Sweden. J Anal Toxicol 28 (2004) 67-70
5. Staack R., and Maurer H. Metabolism of designer drugs of abuse. Curr Drug Metab 6 (2005) 259-274
6. European Monitroing Centre for Drugs and Drug Addiction. Europol-EMCDDA Joint Report on a new psychoactive substance: 1-benzylpiperazine (BZP) (March 23, 2007). http://www.emcdda.europa.eu/?nnodeID=1346 (accessed April 17, 2007).
7. European Monitroing Centre for Drugs and Drug Addiction. Europol-EMCDDA Joint Report on a new psychoactive substance: 1-(3-chlorophenyl)piperazine (mCPP) (March 23, 2007). http://www.emcdda.europa.eu/?nnodeID=1346 (accessed April 17, 2007).
8. Baumann M., Clark R., Budzynski A., Partilla J., Blough B., and Rothman R. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 30 (2005) 550-560
9. Anonymous. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule. Fed Regist 69 (2004) 12794-12797
10. MHRA. Press release: benzylpiperazine (PEP) pills are dangerous and illegal (March 20, 2007). http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSeconda ry=true&ssDocName=CON2030603&ssTargetNodeId=389 (accessed April 17, 2007).
11. Klaassen T., Ho Pian K., Westenberg H., den Boer J., and van Praag H. Serotonin syndrome after challenge with the 5-HT agonist meta-chlorophenylpiperazine. Psychiatry Res 79 (1998) 207-212
12. Maurer H. Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and/or doping control. Clin Chem Lab Med 42 (2004) 1310-1324
13. Peters F., Schaefer S., Staack R., Kraemer T., and Maurer H. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. J Mass Spectrom 38 (2003) 659-676